Form 4: Akoya Biosciences Chief Business Officer Acquires 87,500 Shares Through Restricted Stock Units

Akoya Biosciences' Chief Business Officer, Niro Ramachandran, acquired 87,500 shares of common stock through the vesting of restricted stock units.

Summary

• Niro Ramachandran, Chief Business Officer of Akoya Biosciences, Inc., acquired 87,500 shares of common stock.
• The acquisition was through the vesting of restricted stock units, with a price of $0 per unit.
• Following the transaction, Ramachandran directly owns 295,424 shares of Akoya Biosciences common stock.
• The restricted stock units vest over a period of time, with 50% vesting on the first anniversary of the grant date, and the remaining 50% vesting in four equal installments over the following year.

Sentiment

Score: 7

Explanation: The document reflects a routine executive compensation transaction, which is generally viewed neutrally to slightly positive as it aligns executive interests with company performance.

Positives

• The acquisition of shares by a key executive can be seen as a positive sign of confidence in the company's future.

Industry Context

This is a standard transaction for executive compensation in publicly traded companies, where restricted stock units are used to align executive interests with shareholder value.

Comparison to Industry Standards

• The use of restricted stock units for executive compensation is a common practice among publicly traded companies, including those in the biotechnology and life sciences sectors, such as Illumina, Inc. and Bio-Rad Laboratories, Inc.
• Vesting schedules for restricted stock units typically range from one to four years, with a common structure being a one-year cliff followed by quarterly or monthly vesting, similar to the schedule described in this document.

Stakeholder Impact

• The transaction has a minor positive impact on shareholders as it aligns executive interests with company performance.

Key Dates

Keywords

Akoya Biosciences, Niro Ramachandran, restricted stock units, share acquisition, insider trading, executive compensation, equity